Robert W. Baird Begins Coverage on Chimerix (NASDAQ:CMRX)

Posted by Amanda Harley on May 26th, 2023

Robert W. Baird assumed coverage on shares of Chimerix (NASDAQ:CMRX – Get Rating) in a research note issued to investors on Monday, The Fly reports. The brokerage issued an outperform rating and a $7.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright reiterated a buy rating and issued a $11.00 target price on shares of Chimerix in a report on Friday, March 3rd. StockNews.com initiated coverage on Chimerix in a research report on Thursday, May 18th. They set a hold rating on the stock.

Chimerix Stock Down 5.6 %

Shares of Chimerix stock opened at $1.36 on Monday. Chimerix has a 52 week low of $1.09 and a 52 week high of $2.90. The business has a 50 day moving average of $1.21 and a 200 day moving average of $1.64. The company has a market cap of $120.47 million, a PE ratio of 0.68 and a beta of 1.15.

Chimerix (NASDAQ:CMRX – Get Rating) last announced its earnings results on Thursday, March 2nd. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.24). The business had revenue of $0.81 million for the quarter, compared to analysts’ expectations of $2.60 million. Chimerix had a return on equity of 87.89% and a net margin of 514.97%. During the same period last year, the firm posted ($0.45) earnings per share. On average, research analysts anticipate that Chimerix will post -0.92 earnings per share for the current year.

Insider Activity at Chimerix

In other news, CFO Michael T. Andriole bought 51,700 shares of the business’s stock in a transaction dated Thursday, May 18th. The shares were acquired at an average price of $1.14 per share, for a total transaction of $58,938.00. Following the completion of the transaction, the chief financial officer now owns 357,015 shares of the company’s stock, valued at $406,997.10. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders purchased 98,450 shares of company stock worth $113,093. Company insiders own 8.20% of the company’s stock.

Institutional Investors Weigh In On Chimerix

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in Chimerix by 4.1% during the 1st quarter. Geode Capital Management LLC now owns 1,638,302 shares of the biopharmaceutical company’s stock valued at $2,064,000 after buying an additional 65,250 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Chimerix by 12.8% in the first quarter. AQR Capital Management LLC now owns 1,904,995 shares of the biopharmaceutical company’s stock worth $2,400,000 after acquiring an additional 216,558 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Chimerix by 2.4% during the first quarter. Armistice Capital LLC now owns 3,276,000 shares of the biopharmaceutical company’s stock valued at $4,128,000 after buying an additional 76,000 shares during the last quarter. Deutsche Bank AG raised its holdings in Chimerix by 33.8% during the first quarter. Deutsche Bank AG now owns 56,308 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 14,240 shares in the last quarter. Finally, XTX Topco Ltd grew its position in Chimerix by 65.6% in the first quarter. XTX Topco Ltd now owns 233,342 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 92,465 shares during the last quarter. Hedge funds and other institutional investors own 58.03% of the company’s stock.

Chimerix Company Profile

(Get Rating)

Chimerix, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.